Search

Ion Beam Applications

Open

10.6 -3.28

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.6

Max

11.08

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

Verkoop

206M

K/W

Sectorgemiddelde

41.111

63.778

Dividendrendement

1.56

Winstmarge

-4.99

Werknemers

1,943

EBITDA

-372K

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.56%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

342M

Vorige openingsprijs

13.88

Vorige sluitingsprijs

10.6

Ion Beam Applications Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 sep 2024, 06:28 UTC

Acquisities, Fusies, Overnames

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.